Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JMW5 | ISIN: CA6823108759 | Ticker-Symbol: ONYN
Berlin
30.06.25 | 09:15
0,580 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOLYTICS BIOTECH INC Chart 1 Jahr
5-Tage-Chart
ONCOLYTICS BIOTECH INC 5-Tage-Chart

Aktuelle News zur ONCOLYTICS BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ONCOLYTICS BIOTECH Aktie jetzt für 0€ handeln
MoStocks in Play: Oncolytics Biotech Inc.2
MoStocks in Play: Oncolytics Biotech Inc2
MoONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer2
MoOncolytics Biotech appoints Andrew Aromando as chief business officer3
MoOncolytics Biotech Inc.: Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy193SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing...
► Artikel lesen
11.06.Oncolytics Biotech stock takes off after naming new CEO3
11.06.Stocks in Play: Oncolytics Biotech Inc.2
11.06.Stocks in Play: Oncolytics Biotech Inc-
11.06.Oncolytics names Jared Kelly as CEO2
11.06.ONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer2
11.06.Oncolytics Biotech Inc.: Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs289SAN DIEGO and CALGARY, AB, June 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in...
► Artikel lesen
23.05.Stocks in Play: Oncolytics Biotech Inc-
23.05.Stocks in Play: Oncolytics Biotech® Inc.1
23.05.ONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer1
23.05.Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities8
15.05.Stocks in Play: Oncolytics Biotech Inc5
14.05.Oncolytics Biotech GAAP EPS of -$0.08 misses by $0.011
14.05.Oncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum136American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key...
► Artikel lesen
13.05.A Look at Oncolytics Biotech's Upcoming Earnings Report1
08.05.ONCOLYTICS BIOTECH INC - 6-K, Report of foreign issuer1
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1